Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05819775 · ClinicalTrials.gov registry record · Phase 3
CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema
A Phase 3 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 3
- Development phase
- 22
- Enrollment target
NCT05819775 is a Phase 3 study that has completed, run by CSL Behring. The registered enrollment target is 22 participants.
The verdict
NCT05819775, a Phase 3 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety, PK / PD, and efficacy of SC CSL312 for prophylactic treatment of pediatric subjects with HAE.
Interventions
- BIOLOGICAL CSL312
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-05-30 |
| Est. Completion | 2025-11-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05819775
The ClinicalTrials.gov registry entry for NCT05819775 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CSL312 is the first listed.
NCT05819775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05819775 about?
NCT05819775 is a clinical study titled "CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema". The purpose of this study is to investigate the safety, PK / PD, and efficacy of SC CSL312 for prophylactic treatment of pediatric subjects with HAE.
What is the current status of trial NCT05819775?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 22 participants. The study started on 2023-05-30. Estimated completion is 2025-11-19.
What interventions are being tested in trial NCT05819775?
The interventions under investigation include: CSL312 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05819775?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.